Member Login
  1. Stocks
    2. /
  2. Bausch Health Companies Inc. (NYSE: BHC)
    3. /

NYSE:BHC (Bausch Health Companies Inc.)

About BHC

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Bausch Health Companies Inc. (NYSE: BHC) Latest News

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. in Talks to Sell $10 Billion Division: What Now?

    | Jacob Donnelly

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had big news on Tuesday. Investors need to be patient and wait.

    Read more »

    The Motley Fool
    Investing

    The Real Reason Why Bill Ackman Still Holds Valeant Pharmaceuticals Intl Inc.

    | Joey Frenette

    Valeant Pharmaceutical Intl Inc. (TSX:VRX)(NYSE:VRX) has fallen so much that there might be some value to be had. Bill Ackman…

    Read more »

    The Motley Fool
    Investing

    Why Valeant Pharmaceuticals Intl Inc. Is the Best Contrarian Pick for 2017

    | Chris MacDonald

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a newly minted value stock, which offers an interesting entry point for long-term investors.…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Turnaround Candidate or Racing to the Bottom?

    | Demetris Afxentiou

    Valent Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is making all of the right business decisions, but it may not be enough to…

    Read more »

    The Motley Fool
    Investing

    Concordia International Corp.: A Safe Buy?

    | Jacob Donnelly

    Concordia International Corp. (TSX:CXR)(NASDAQ:CXRX) is a risky, debt-ridden company that could grow quite handsomely if a series of steps are…

    Read more »

    The Motley Fool
    Investing

    Should You Buy Valeant Pharmaceuticals Intl Inc.?

    | Jacob Donnelly

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a risky buy, even if it can get its debt under control--and that's a…

    Read more »

    The Motley Fool
    Dividend Stocks

    3 Dirty Secrets Bay Street Doesn’t Want You to Know

    | Nelson Smith

    Be wary of what Bay Street bankers and analysts tell you, especially when they tout stocks such as Valeant Pharmaceuticals…

    Read more »

    The Motley Fool
    Investing

    More Problems for Valeant Pharmaceuticals Intl Inc.

    | Demetris Afxentiou

    Problems continue to mount for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). The company now faces a number of lawsuits in addition…

    Read more »

    The Motley Fool
    Investing

    The Smart Money Is Buying Valeant Pharmaceuticals Intl Inc.: Should You Buy Too?

    | Nelson Smith

    Famed mutual fund manager Francis Chou is buying Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). What does he see in the troubled…

    Read more »

    The Motley Fool
    Investing

    Can Valeant Pharmaceuticals Intl Inc. Recover From its Implosion?

    | Jacob Donnelly

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) might seem like it's on its last breath, but it has made smart moves that…

    Read more »

    The Motley Fool
    Dividend Stocks

    How Will a Trump or Clinton Presidency Affect Your Portfolio?

    | Nelson Smith

    Do you own Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) or TransCanada Corporation (TSX:TRP)(NYSE:TRP) shares? Then pay attention to this election cycle.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: This Risky Stock Has Huge Upside

    | Nelson Smith

    After falling 90%, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been written off for dead. But perhaps value investors might want…

    Read more »